A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guerin (BCG) against Mycobacterium tuberculosis.

ABSTRACT:

Background

Approximately 80% - 90% of individuals infected with latent Mycobacterium tuberculosis (Mtb) remain protected throughout their life-span. The release of unique, latent-phase antigens are known to have a protective role in the immune response against Mtb. Although the BCG vaccine has been administered for nine decades to provide immunity against Mtb, the number of TB cases continues to rise, thereby raising doubts on BCG vaccine efficacy. The shortcomings of BCG have been associated with inadequate processing and presentation of its antigens, an inability to optimally activate T cells against Mtb, and generation of regulatory T cells. Furthermore, BCG vaccination lacks the ability to eliminate latent Mtb infection. With these facts in mind, we selected six immunodominant

SUBMITTER: Maurya SK 

PROVIDER: S-EPMC7495405 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature